TITLE

Optimism dominates AIDS vaccine confab

AUTHOR(S)
ROEHR, BOB
PUB. DATE
October 2010
SOURCE
Windy City Times;10/6/2010, Vol. 26 Issue 1, p4
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article offers a look at the efforts launched to study HIV infection and AIDS vaccine.
ACCESSION #
55231951

 

Related Articles

  • AIDS Vaccines: Progress and Unmet Challenges. Bolognesi, Dani P. // Annals of Internal Medicine;1/15/91, Vol. 114 Issue 2, p161 

    Editorial. Focuses on the progress of the development of HIV or AIDS vaccines. Issues ignored in developing a vaccine; Models used in clinical trials; Recommendations for the design of clinical trials.

  • Gender differences in HIV-1 diversity at time of infection. Michelle Long, E.; Martin, Harold L.; Kreiss, Joan K.; Rainwater, Stephanie M.J.; Lavreys, Ludo; Jackson, Denis J.; Rakwar, Joel; Mandaliya, Kishorchandra; Overbaugh, Julie // Nature Medicine;Jan2000, Vol. 6 Issue 1, p71 

    To develop an HIV-1 vaccine with global efficacy, it is important to identify and characterize the viruses that are transmitted, particularly to individuals living in areas of high incidence. Several studies have shown that virus from the blood of acutely infected adults was homogeneous, even...

  • Microbicides 2002: An Update. Johnston, Rowena // AIDS Patient Care & STDs;Sep2002, Vol. 16 Issue 9, p419 

    Given that an acquired immune deficiency syndrome (AIDS) vaccine is more likely to mitigate than avert human immunodeficiency virus (HIV) infection, prevention efforts are focused on the development of a microbicide to reduce the sexual transmission of HIV. In this context, a microbicide might...

  • Hitting HIV with a double whammy. Cohen, Philip // New Scientist;8/4/2001, Vol. 171 Issue 2302, p6 

    Provides information on a combined approach to AIDS vaccine that would protect against the disease. Effect of AIDS vaccine on the immunological response of the body; Process of infecting the antigen dendritic cells, a form of vaccination strategy.

  • Vaccine setback. Day, Michael // New Scientist;10/18/97, Vol. 156 Issue 2104, p7 

    Reports on the study showing the role of HIV's vpr gene in suppressing the immune system. Effects of the protein made by the vpr gene on the rate of division in cultures of T cells; Implications of the removal of the gene in the design of HIV vaccine.

  • Who will pay for HIV's big push? Brown, Phyllida // New Scientist;4/6/96, Vol. 150 Issue 2024, p6 

    Focuses on the Joint UN Programme on HIV/AIDS' (UNAIDS) call for funding for research which will study several HIV strains and could change the approach to vaccine design. Explanation on why heterosexuals in Africa and Asia are more easily affected as compared to those in Europe and North...

  • Preface [Hot Topic: Anti - HIV Design (Executive Editor : K. Parang)]. Parang, Keykavous // Current Pharmaceutical Design;Aug2003, Vol. 9 Issue 22, p1 

    The selection of topics and authors was made with the intention to complement the first issue of anti-HIV Drug Design (Current Pharmaceutical Design, 2002, Volume 8, number 8). These articles present alternative approaches other than available chemotherapeutic agents against Human...

  • The search for an HIV vaccine. Makgoba, Malegapuru William; Solomon, Nandipha; Tucker, Timothy Johan Paul // BMJ: British Medical Journal (International Edition);01/26/2002, Vol. 324 Issue 7331, p211 

    Comments on the outlook for an effective vaccine against HIV. Political, scientific, and other factors which will influence whether an appropriate HIV vaccine is developed; Target populations for an HIV vaccine; Increase in the number of described HIV subtypes; Conclusion that the development...

  • First trial of the HIV-1 vaccine in Africa: Ugandan experience. Mugerwa, Roy D; Kaleebu, Pontiano; Mugyenyi, Peter; Katongole-Mbidde, Edward; Hom, David L; Byaruhanga, Rose; Salata, Robert A; Ellner, Jerrold J // BMJ: British Medical Journal (International Edition);01/26/2002, Vol. 324 Issue 7331, p226 

    Describes problems in setting up the first trial of an HIV-1 vaccine in Uganda, explanations of how the problems were solved, and suggestions to help researchers who are starting future trials of HIV vaccines. Social, behavioral, and ethical issues; Scientific issues, including perceived risks...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics